2,4-Dibromotoluene | CAS:31543-75-6

We serve 2,4-Dibromotoluene CAS:31543-75-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4-Dibromotoluene

Chemical Name:2,4-Dibromotoluene
CAS.NO:31543-75-6
Synonyms:2,4-Dibromotoluene
2,4-dibromo-1-methylbenzene
 
Physical and Chemical Properties:
Density 1.8±0.1 g/cm3
Boiling Point 241.9±20.0 °C at 760 mmHg
Melting Point -10 °C
Molecular Formula C7H6Br2
Molecular Weight 249.930
Flash Point 109.0±21.0 °C
Vapour Pressure 0.1±0.5 mmHg at 25°C
Index of Refraction 1.588
 
Specification:
Appearance:Light yellow liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2,4-Dibromotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-dibromo-1-methylbenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-dibromo-1-methylbenzene Use and application,2,4-Dibromotoluene technical grade,usp/ep/jp grade.


Related News: The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs.9-Bromo-10-(1-Naphthalenyl)Anthracene manufacturer The safety and effectiveness of TCM is still debated in China, where it has both adherents and skeptics.(R)-2-AMINO-3-BENZYLOXY-1-PROPANOL supplier Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California.2-Bromo-4-fluoroaniline vendor In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.